Separation and quantification of a novel two-component vaccine adjuvant.
Two reversed-phase HPLC methods were developed for the quantitative determination of the two components of the novel vaccine adjuvant IC31. The adjuvant consists of a mixture of a synthetic oligodeoxynucleotide (ODN) and an 11-mer cationic peptide. The negatively charged oligodeoxynucleotide and the positively charged peptide form a complex that has to be quantitatively dissociated for analysis. Dissociation of the complex was achieved with a basic heparin solution (1000 IU/ml) when analyzing the ODN, whereas 30% acetic acid was used for the determination of the peptide. Both methods are suitable for identification and quantification but also for stability indicating investigations.
Kritsch
Constantia E
CE
Intercell AG, Pharmaceutical Development, Campus Vienna Biocenter 6, A-1030 Vienna, Austria. ckritsch@intercell.com
Berger
Agnes
A
Heinrich-Cseh
Christa
C
Bugajska-Schretter
Agnes
A
Zauner
Wolfgang
W
D000276:Adjuvants, Immunologic / Q000032:analysis* / Q000302:isolation & purification*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004355:Drug Stability; D009841:Oligonucleotides / Q000032:analysis* / Q000302:isolation & purification*; D010455:Peptides / Q000032:analysis* / Q000302:isolation & purification*; D013601:T-Lymphocytes / Q000502:physiology*; D014612:Vaccines / Q000138:chemical synthesis* / Q000276:immunology
D000276:Adjuvants, Immunologic; D009841:Oligonucleotides; D010455:Peptides; D014612:Vaccines